Starling Oncology Stock Forecast
NASDAQ: STLNHealth CareMedical/Nursing ServicesUSD
At close: Oct 8, 4:00 PM ET · Delayed 15 min
After hours: 6.21 +0.49%
STLN analyst consensus
Consensus (5 analysts)
strong_buy
Avg. price target
$9.00+45.63%
- Strong buy 1
- Buy 4
- Hold 0
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
What analysts say
According to 5 Wall Street analysts covering Starling Oncology (2026-10-08), 5 rate the stock a buy or strong buy, 0 rate it a hold and 0 rate it a sell or strong sell, for a consensus rating of "strong_buy". The average 12-month price target is $9.00, with a high estimate of $11.00 and a low estimate of $7.00. The average target implies upside of 45.6% from the current price of $6.18.
The spread between the highest and lowest targets is 57.1%, a relatively narrow range. Price targets and ratings are the opinions of third-party analysts, not MetaCap. They are frequently revised and have a mixed track record, so treat them as one input among many for STLN.
Summary generated from market data by MetaCap's automated system. Methodology
Rating distribution
| Rating | Analysts | Share |
|---|---|---|
| Strong buy | 1 | 20% |
| Buy | 4 | 80% |
| Hold | 0 | 0% |
| Sell | 0 | 0% |
| Strong sell | 0 | 0% |
Ratings as of 2026-10-08.
Price target scenarios
| Target | Price | vs. current |
|---|---|---|
| Low target | $7.00 | +13.27% |
| Average target | $9.00 | +45.63% |
| High target | $11.00 | +77.99% |